USD 0.0
(-3.92%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -27.79 Thousand USD | -26.26% |
2022 | -22.01 Thousand USD | 71.71% |
2021 | -77.79 Thousand USD | -45.89% |
2020 | -53.32 Thousand USD | -513.58% |
2019 | -8690.00 USD | 80.24% |
2018 | -43.98 Thousand USD | -663.85% |
2017 | 7800.00 USD | 0.0% |
2015 | -126.92 Thousand USD | 42.24% |
2014 | -219.75 Thousand USD | -47484.2% |
2013 | -461.81 USD | 0.0% |
2009 | -12.39 Thousand USD | 92.76% |
2008 | -171.19 Thousand USD | 82.79% |
2007 | -994.58 Thousand USD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | -2450.00 USD | 53.51% |
2024 Q1 | -5270.00 USD | 62.25% |
2023 Q2 | -3330.00 USD | -22.88% |
2023 Q1 | -2710.00 USD | 63.67% |
2023 Q4 | -13.96 Thousand USD | -174.8% |
2023 FY | -27.79 Thousand USD | -26.26% |
2023 Q3 | -5080.00 USD | -52.55% |
2022 FY | -22.01 Thousand USD | 71.71% |
2022 Q2 | -8170.00 USD | -65.72% |
2022 Q3 | -1460.00 USD | 82.13% |
2022 Q4 | -7460.00 USD | -410.96% |
2022 Q1 | -4930.00 USD | 20.1% |
2021 Q3 | -3790.00 USD | 25.39% |
2021 Q4 | -6170.00 USD | -62.8% |
2021 Q1 | -62.74 Thousand USD | 0.0% |
2021 FY | -77.79 Thousand USD | -45.89% |
2021 Q2 | -5080.00 USD | 91.9% |
2020 FY | -53.32 Thousand USD | -513.58% |
2019 FY | -8690.00 USD | 80.24% |
2018 FY | -43.98 Thousand USD | -663.85% |
2017 FY | 7800.00 USD | 0.0% |
2015 FY | -126.92 Thousand USD | 42.24% |
2014 Q2 | -65.77 USD | -1.04% |
2014 FY | -219.75 Thousand USD | -47484.2% |
2014 Q3 | -49.73 USD | 24.39% |
2014 Q1 | -65.09 USD | 69.81% |
2014 Q4 | -39.00 USD | 21.57% |
2013 Q3 | -73.75 USD | 19.56% |
2013 FY | -461.81 USD | 0.0% |
2013 Q4 | -215.58 USD | -192.32% |
2013 Q2 | -91.68 USD | -15.73% |
2013 Q1 | -79.22 USD | 0.0% |
2010 Q3 | -70.48 Thousand USD | 29.94% |
2010 Q1 | -96.22 Thousand USD | -4546.4% |
2010 Q2 | -100.59 Thousand USD | -4.54% |
2009 FY | -12.39 Thousand USD | 92.76% |
2009 Q4 | -2071.00 USD | 25.58% |
2009 Q1 | -5943.00 USD | 0.0% |
2009 Q3 | -2783.00 USD | -74.05% |
2009 Q2 | -1599.00 USD | 73.09% |
2008 FY | -171.19 Thousand USD | 82.79% |
2007 Q1 | -369.01 Thousand USD | 0.0% |
2007 Q2 | -370.75 Thousand USD | -0.47% |
2007 FY | -994.58 Thousand USD | 0.0% |
2006 Q2 | -468.4 Thousand USD | -37.22% |
2006 Q1 | -341.35 Thousand USD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
China Medicine Corporation | 12.26 Million USD | 100.227% |
DH Enchantment Inc. | -145.23 Thousand USD | 80.866% |
Exlites Holdings International, Inc. | -15.49 Thousand USD | -79.406% |
Itonis, Inc. | -38.31 Thousand USD | 27.46% |
MediPal Holdings Corporation | 312.71 Million USD | 100.009% |
PD-Rx Pharmaceuticals, Inc. | -190.47 Thousand USD | 85.41% |
Pharmagen, Inc. | -2159.03 USD | -1187.152% |
Suzuken Co., Ltd. | 230.42 Million USD | 100.012% |